NASDAQ:VYGR - Voyager Therapeutics Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Voyager Therapeutics Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $10.60 -0.43 (-3.90 %) (As of 02/28/2020 04:42 AM ET) Add Compare Today's Range$10.32Now: $10.60▼$11.1450-Day Range$10.60MA: $12.80▼$14.6652-Week Range$10.32Now: $10.60▼$28.79Volume330,525 shsAverage Volume314,111 shsMarket Capitalization$392.97 millionP/E RatioN/ADividend YieldN/ABeta2.51 ProfileAnalyst RatingsAdvanced ChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Voyager Therapeutics, Inc, a clinical-stage gene therapy company, focuses on the development of treatments for patients suffering from severe neurological diseases. The company's lead clinical candidate is the VY-AADC, which is in open-label Phase 1b clinical trial for the treatment of Parkinson's disease. Its preclinical programs comprise VY-SOD101 for the treatment of amyotrophic lateral sclerosis; VY-HTT01 for Huntington's disease; VY-FXN01 for Friedreich's ataxia; Tau program for the treatment of tauopathies, including Alzheimer's disease, progressive supranuclear palsy, and frontotemporal dementia; and VY-NAV01 for severe chronic pain. Read More… Industry, Sector and Symbol Stock Exchange NASDAQ Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:VYGR Previous Symbol CUSIPN/A CIK1640266 Webhttp://www.voyagertherapeutics.com/ Phone857-259-5340Debt Debt-to-Equity RatioN/A Current Ratio4.09 Quick Ratio4.09Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$7.62 million Price / Sales51.57 Cash FlowN/A Price / Cash FlowN/A Book Value$1.43 per share Price / Book7.41Profitability EPS (Most Recent Fiscal Year)($2.75) Net Income$-88,290,000.00 Net Margins-72.64% Return on Equity-57.32% Return on Assets-15.83%Miscellaneous Employees123 Outstanding Shares37,073,000Market Cap$392.97 million Next Earnings Date3/3/2020 (Confirmed) OptionableOptionable Receive VYGR News and Ratings via Email Sign-up to receive the latest news and ratings for VYGR and its competitors with MarketBeat's FREE daily newsletter. NASDAQ:VYGR Rates by TradingView Voyager Therapeutics (NASDAQ:VYGR) Frequently Asked Questions What is Voyager Therapeutics' stock symbol? Voyager Therapeutics trades on the NASDAQ under the ticker symbol "VYGR." How were Voyager Therapeutics' earnings last quarter? Voyager Therapeutics Inc (NASDAQ:VYGR) announced its quarterly earnings results on Wednesday, November, 6th. The company reported ($0.41) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.83) by $0.42. The company earned $20.43 million during the quarter, compared to the consensus estimate of $3.94 million. Voyager Therapeutics had a negative net margin of 72.64% and a negative return on equity of 57.32%. View Voyager Therapeutics' Earnings History. When is Voyager Therapeutics' next earnings date? Voyager Therapeutics is scheduled to release their next quarterly earnings announcement on Tuesday, March 3rd 2020. View Earnings Estimates for Voyager Therapeutics. How can I listen to Voyager Therapeutics' earnings call? Voyager Therapeutics will be holding an earnings conference call on Tuesday, March 3rd at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available. What price target have analysts set for VYGR? 8 brokerages have issued 12-month price objectives for Voyager Therapeutics' stock. Their forecasts range from $18.00 to $37.00. On average, they expect Voyager Therapeutics' share price to reach $28.00 in the next twelve months. This suggests a possible upside of 164.2% from the stock's current price. View Analyst Price Targets for Voyager Therapeutics. What is the consensus analysts' recommendation for Voyager Therapeutics? 8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Voyager Therapeutics in the last year. There are currently 2 hold ratings and 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Voyager Therapeutics. What are Wall Street analysts saying about Voyager Therapeutics stock? Here are some recent quotes from research analysts about Voyager Therapeutics stock: 1. According to Zacks Investment Research, "Voyager Therapeutics, Inc. is a gene therapy company. It focuses on the development of treatments for patients suffering from severe diseases of the central nervous system. Its pipeline includes VY-AADC01, which is in Phase 1b clinical trials for treatment of Parkinson's disease and preclinical programs comprise VY-SOD101 for a monogenic form of amyotrophic lateral sclerosis, VY-FXN01 for Friedreich ataxia and VY-HTT01 for Huntington's disease as well as VY-SMN101 for neuromuscular disease. Voyager Therapeutics, Inc. is headquartered in Cambridge, Massachusetts. " (1/25/2020) 2. Nomura analysts commented, "Minor Tweaks Post-NBIX Collab., Revising Patient Numbers and Statistical Plan; No Data Guidance Yet. The first pivotal Parkinson’s disease trial, RESTORE-1, is undergoing minor modifications now that VYGR is partnered with NBIX. VYGR had previously guided to a 75-100 patient trial, but this is likely going to be clarified as the statistical analysis plan is finalized. No data guidance yet—but we expect an update when the target enrollment is finalized and when VYGR gets a sense of the pace of enrollment. Huntington’s Program IND by YE19 – Finalizing Clinical Team and Planning to Use Commercial-Grade Gene Therapy Material. Voyager recently attained full rights after the SNY collaboration restructuring (see our note here). VYGR plans to have an IND by YE19 and will use material that is “very, very similar” to commercial material to avoid any step back in the future." (8/13/2019) 3. HC Wainwright analysts commented, "Our current target is based on a 12-year DCF analysis primarily focused on VY-AADC in PD. Our DCF analysis is based on: beta of 1.62, terminal growth rate of 0.5%, risk premium of 4.93%, calculated WACC of 10.0%, and tax rate of 15% beginning in FY 2030." (8/12/2019) Has Voyager Therapeutics been receiving favorable news coverage? Media stories about VYGR stock have trended negative recently, InfoTrie reports. InfoTrie rates the sentiment of news coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. Voyager Therapeutics earned a news impact score of -2.7 on InfoTrie's scale. They also assigned news coverage about the company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an impact on the stock's share price in the immediate future. View News Stories for Voyager Therapeutics. Who are some of Voyager Therapeutics' key competitors? Some companies that are related to Voyager Therapeutics include Regenxbio (RGNX), SpringWorks Therapeutics (SWTX), Cortexyme (CRTX), Coherus Biosciences (CHRS), NanoString Technologies (NSTG), Editas Medicine (EDIT), Beam Therapeutics (BEAM), Twist Bioscience (TWST), Orchard Therapeutics (ORTX), BAVARIAN NORDIC/S (BVNRY), I-Mab (BDTX), Krystal Biotech (KRYS), Oyster Point Pharma (OYST), DBV TECHNOLOGIE/S (DBVT) and Adverum Biotechnologies (ADVM). What other stocks do shareholders of Voyager Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Voyager Therapeutics investors own include TG Therapeutics (TGTX), Crispr Therapeutics (CRSP), Micron Technology (MU), AbbVie (ABBV), ImmunoGen (IMGN), Sangamo Therapeutics (SGMO), Editas Medicine (EDIT), Exelixis (EXEL), Sorrento Therapeutics (SRNE) and Cara Therapeutics (CARA). Who are Voyager Therapeutics' key executives? Voyager Therapeutics' management team includes the folowing people: Mr. Matthew P. Ottmer, Chief Operating Officer (Age 48)Dr. Steven M. Paul, Exec. Science Advisor & Director (Age 68)Mr. G. Andre Turenne, CEO, Pres & DirectorDr. Krystof Bankiewicz M.D., Ph.D., FounderDr. Guangping Gao Ph.D., Founder Who are Voyager Therapeutics' major shareholders? Voyager Therapeutics' stock is owned by many different of retail and institutional investors. Top institutional shareholders include State Street Corp (3.58%), Renaissance Technologies LLC (3.36%), Casdin Capital LLC (2.95%), Bank of New York Mellon Corp (1.50%), Goldman Sachs Group Inc. (1.13%) and Geode Capital Management LLC (1.04%). Company insiders that own Voyager Therapeutics stock include Allison Dorval, Andre Turenne, Bernard Ravina, Glenn Pierce, James A Geraghty, Jane Henderson, Matthew P Ottmer and Neurocrine Biosciences Inc. View Institutional Ownership Trends for Voyager Therapeutics. Which major investors are selling Voyager Therapeutics stock? VYGR stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, UBS Group AG, State Street Corp, Bank of America Corp DE, Citigroup Inc., Rafferty Asset Management LLC, Raymond James Financial Services Advisors Inc. and Jacobs Levy Equity Management Inc.. Company insiders that have sold Voyager Therapeutics company stock in the last year include Allison Dorval, Andre Turenne and Matthew P Ottmer. View Insider Buying and Selling for Voyager Therapeutics. Which major investors are buying Voyager Therapeutics stock? VYGR stock was acquired by a variety of institutional investors in the last quarter, including Bank of New York Mellon Corp, Renaissance Technologies LLC, Bank of Montreal Can, Acadian Asset Management LLC, Russell Investments Group Ltd., Alberta Investment Management Corp, Man Group plc and Bailard Inc.. Company insiders that have bought Voyager Therapeutics stock in the last two years include Glenn Pierce, James A Geraghty and Neurocrine Biosciences Inc. View Insider Buying and Selling for Voyager Therapeutics. How do I buy shares of Voyager Therapeutics? Shares of VYGR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab. What is Voyager Therapeutics' stock price today? One share of VYGR stock can currently be purchased for approximately $10.60. How big of a company is Voyager Therapeutics? Voyager Therapeutics has a market capitalization of $392.97 million and generates $7.62 million in revenue each year. The company earns $-88,290,000.00 in net income (profit) each year or ($2.75) on an earnings per share basis. Voyager Therapeutics employs 123 workers across the globe.View Additional Information About Voyager Therapeutics. What is Voyager Therapeutics' official website? The official website for Voyager Therapeutics is http://www.voyagertherapeutics.com/. How can I contact Voyager Therapeutics? Voyager Therapeutics' mailing address is 75 SIDNEY STREET, CAMBRIDGE MA, 02139. The company can be reached via phone at 857-259-5340 or via email at [email protected] MarketBeat Community Rating for Voyager Therapeutics (NASDAQ VYGR)Community Ranking: 2.7 out of 5 ( )Outperform Votes: 330 (Vote Outperform)Underperform Votes: 280 (Vote Underperform)Total Votes: 610MarketBeat's community ratings are surveys of what our community members think about Voyager Therapeutics and other stocks. Vote "Outperform" if you believe VYGR will outperform the S&P 500 over the long term. Vote "Underperform" if you believe VYGR will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 2/28/2020 by MarketBeat.com StaffFeatured Article: Closed-End Mutual Funds
